ibusinesslines.com
ibusinesslines.com April 24, 2018


Alder BioPharmaceuticals, Inc. (ALDR) Set to Announce Quarterly Earnings on Monday

17 July 2017, 09:17 | Kelvin Horton

Investors who are keeping close eye on Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) from a strong sell rating to a sell rating in a report issued on Tuesday, June 20th. The stock now has a consensus rating of "Buy" and an average price target of $35.00. Including today's unusual volume, Eiger BioPharmaceuticals, Inc.'s stock is performing at -20.60% on the year. It discovers, develops and seeks to commercialize therapeutic antibodies. Needham maintained the shares of ALDR in report on Thursday, June 8 with "Buy" rating. Aegis restated a "buy" rating and set a $41.00 price objective on shares of Alder BioPharmaceuticals in a research report on Wednesday, July 5th. Jefferies Group LLC restated a buy rating and set a $43.00 target price on shares of Alder BioPharmaceuticals in a report on Monday, April 17th. Finally, Oppenheimer Holdings, Inc. set a $34.00 target price on shares of Eiger BioPharmaceuticals and gave the stock a buy rating in a report on Saturday, April 8th. Alder Biopharmaceuticals had 19 analyst reports since August 6, 2015 according to SRatingsIntel. Also, there are 1 buy, 0 sell and 1 strong sell ratings, collectively assigning a 1.63 average brokerage recommendation. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of "Buy" and a consensus target price of $27.75. The company's stock had a trading volume of 91,683 shares. Eiger BioPharmaceuticals has a 52-week low of $6.10 and a 52-week high of $20.63. The stock has a 50-day moving average of $7.05 and a 200 day moving average of $9.94. This company shares are 208.07% off its target price of $35.89 and the current market capitalization stands at $584.83M. Over the last three months, the shares of the company have changed 8.82% and performed -21.28% over the last six months. On average, equities research analysts expect that Eiger BioPharmaceuticals will post ($5.39) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of worldwide copyright & trademark legislation. The legal version of this news story can be accessed at https://www.com-unik.info/2017/07/17/alder-biopharmaceuticals-inc-aldr-set-to-announce-quarterly-earnings-on-monday.html.


Several other institutional investors also recently made changes to their positions in ALDR. Fox Run Management L.L.C. purchased a new position in shares of Alder BioPharmaceuticals during the second quarter worth about $402,000. Zero analysts have provided estimates for Eiger BioPharmaceuticals' earnings, with the lowest EPS estimate coming in at ($1.51) and the highest estimate coming in at ($0.93). Bank of New York Mellon Corp boosted its position in shares of Eiger BioPharmaceuticals by 4.7% in the first quarter. Janus Capital Management LLC now owns 5,167,085 shares of the biopharmaceutical company's stock worth $107,473,000 after buying an additional 230,044 shares during the period. Bank of New York Mellon Corp now owns 13,696 shares of the biotechnology company's stock worth $157,000 after buying an additional 614 shares during the period. Finally, Vanguard Group Inc. raised its stake in Eiger BioPharmaceuticals by 1.6% in the first quarter. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.



Other News

Trending Now

Swiss National Bank Has $1805000 Position in Dominion Diamond Corporation (DDC)
The basic materials company reported $0.09 EPS for the quarter, beating the Zacks' consensus estimate of $0.05 by $0.04. Wall Street is only getting more bullish on the stock, with 4 of analysts who cover DDC having a buy-equivalent rating.

Twin Cities man blames autopilot after Tesla rolls into marsh
Additionally, every time that Autopilot is engaged, the vehicle reminds the driver to "Always keep your hands on the wheel". His SUV was parked in his garage when it unexpectedly crashed into his living room, injuring him and destroying walls.

$0.71 EPS Expected for Chemours Co (CC)
Finally, ValuEngine upgraded Chemours Company (The) from a "hold" rating to a "buy" rating in a research note on Friday, June 2nd. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink .

Jay-Z Snags His 14th No. Album with '4:44'
The album, Jay-Z's first in four years, won favorable reviews and marked growing introspection from the 47-year-old rapper. Ever since Vol. 2.Hard Knock Life which came out in 1998, every one of Hov's solo efforts have reached the top spot.

Sergio Romero will stay and fight for his place at Manchester united
Click through the gallery above to see some of the best tweets as fans fear Romero's new deal could see De Gea's departure . Romero was a free transfer under Louis van Gaal two years ago but has impressed current boss Jose Mourinho .

DHS Approves 15000 Additional Temporary Worker Visas
To receive the visas, businesses must attest they would suffer irreparable harm if they can not bring in those workers. The administration insisted the visa boost is not incompatible with its "America first" pledge.

Wimbledon doubles joy for Kubot and Melo as final goes the distance
The partnership of the Polish and the Brazilian has achieved the pair the title of the Wimbledon Men's Double winners. The match being played at the Centre Court was suspended at 11-11 and then resumed with the roof being closed.